Characteristics and outcomes of patients treated with sotrovimab to prevent progression to severe COVID-19 in Belgium.

Myriam DrysdaleThor HautekietMoushmi SinghJoris HautekietLinda LudikhuyzeVishal PatelDaniel C GibbonsDorothée De RoeckKirsten ColpaertEmily J LloydEva Van Braeckel

Published in: Acta clinica Belgica (2024)

This study indicated low rates of COVID-19-related hospitalisations and all-cause deaths in sotrovimab-treated patients in Belgium, including during Omicron subvariant periods, despite over two-thirds of the study population being immunocompromised.

Keyphrases

coronavirus disease
sars cov
newly diagnosed
ejection fraction
end stage renal disease
prognostic factors
type diabetes
early onset
drug induced
respiratory syndrome coronavirus
acute respiratory distress syndrome